Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

This trial is testing a type of precise, high-dose radiation treatment (called HYDRA — stereotactic hypofractionated radioablative therapy) for laryngeal (voice box) cancer, to see if it can be as effective as standard radiation while preserving the voice box and reducing treatment time. **You may be eligible if...** - You are older than 18 - You have been diagnosed with squamous cell carcinoma of the larynx (voice box cancer), confirmed by biopsy - Your cancer is at a specific stage (T1N1, T2, T3, or T4a, with limited lymph node involvement) - Your overall health is good enough for normal daily activities (ECOG 0-2) - A doctor has assessed you as physically eligible for partial larynx surgery (an evaluation checklist is used) - You are able to understand English and sign an informed consent form - If you can become pregnant, you agree to use effective contraception during and for 90 days after treatment **You may NOT be eligible if...** - You have already had surgery to remove the primary tumor - You have previously received radiation to the head and neck area - You have another active cancer - You are pregnant or currently breastfeeding - You cannot understand English or provide consent Talk to your doctor to see if this trial is right for you.